Gilead Acquires Ouro Medicines for $1.675 Billion, Expanding Inflammation Portfolio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GILD?
Source: seekingalpha
- Acquisition Scale: Gilead Sciences announced its acquisition of Ouro Medicines for a total of $1.675 billion, which includes $1.675 billion in upfront cash and up to $500 million in milestone payments, reflecting the company's strong investment intent in the biotech sector.
- Product Line Expansion: This acquisition adds OM336 (gamgertamig) to Gilead's inflammation portfolio, a clinical-stage BCMAxCD3 T cell engager designed for rapid and deep B cell depletion through a limited subcutaneous treatment, expected to enter registrational studies in 2027.
- Collaborative R&D Opportunities: Gilead is in advanced discussions with Galapagos regarding the acquired Ouro Medicines assets, with Galapagos set to cover 50% of the upfront consideration and any milestone payments, indicating strategic collaboration potential in R&D.
- Global Commercialization Rights: Gilead will retain sole worldwide commercialization rights (excluding Greater China), paying Galapagos royalties of 20%-23% of net sales, which will aid Gilead's further expansion in global markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 137.210
Low
105.00
Averages
137.88
High
154.00
Current: 137.210
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GILEAD TO PURCHASE ALL OUTSTANDING EQUITY OF OURO MEDICINES FOR $1.675 BILLION IN CASH UPFRONT
Acquisition Announcement: Gilead will acquire all outstanding equity of Oura for a total of $1.675 billion in upfront cash consideration.
Strategic Move: This acquisition is part of Gilead's strategy to enhance its portfolio in the healthcare sector.
See More
Gilead Sciences to Purchase Ouro Medicines to Enhance Innovative T Cell Engager Initiative for Autoimmune Disorders
Acquisition Announcement: Gilead Sciences has announced its acquisition of Ouro Medical to enhance its capabilities in treating autoimmune diseases.
Focus on Innovation: The acquisition aims to advance Gilead's first-in-class cell engager program, which is designed to target and treat autoimmune conditions more effectively.
See More
Gilead to Provide $1.5 Billion in Cash Upfront to Ouro's Private Investors, with Potential for an Additional $500 Million Based on Clinical Trial Success - FT
- Investment Details: Gilead will pay its privately held investors approximately $1.5 billion upfront in cash.
- Additional Funding: The deal includes at least an extra $500 million tied to specific clinical trial milestones.
See More
Gilead Approaches $2 Billion Agreement with Autoimmune Biotech Ouro Medicines - FT
Gilead's Major Deal: Gilead Sciences is nearing a $2 billion deal focused on autoimmune biotechnologies, indicating a significant investment in this area of medicine.
Focus on Biotech: The deal highlights Gilead's strategic shift towards developing innovative treatments in the biotechnology sector, particularly for autoimmune diseases.
See More
Gilead Acquires Ouro Medicines to Enhance Portfolio
- Acquisition Agreement: Gilead Sciences has entered into a definitive agreement to acquire Ouro Medicines for $1.675 billion in upfront cash, with an additional $500 million in potential milestone payments, aimed at strengthening its portfolio in inflammation and autoimmune diseases.
- Introduction of New Therapy: The acquisition includes OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager designed for rapid and deep B cell depletion, which is expected to enter registrational studies in 2027, demonstrating strong early efficacy and a differentiated safety profile after a single treatment cycle.
- Collaborative R&D Plans: Gilead is in advanced discussions with Galapagos NV for a potential research and development collaboration related to the acquired assets, where Galapagos would fund 50% of the upfront and milestone payments and manage most of Ouro's operations and employees.
- Global Commercialization Rights: Gilead will retain global commercialization rights excluding Greater China and will pay Galapagos royalties ranging from 20% to 23% of net sales, indicating a strategic positioning in the global market.
See More
Gilead Acquires Ouro Medicines for $1.675 Billion, Expanding Inflammation Portfolio
- Acquisition Scale: Gilead Sciences announced its acquisition of Ouro Medicines for a total of $1.675 billion, which includes $1.675 billion in upfront cash and up to $500 million in milestone payments, reflecting the company's strong investment intent in the biotech sector.
- Product Line Expansion: This acquisition adds OM336 (gamgertamig) to Gilead's inflammation portfolio, a clinical-stage BCMAxCD3 T cell engager designed for rapid and deep B cell depletion through a limited subcutaneous treatment, expected to enter registrational studies in 2027.
- Collaborative R&D Opportunities: Gilead is in advanced discussions with Galapagos regarding the acquired Ouro Medicines assets, with Galapagos set to cover 50% of the upfront consideration and any milestone payments, indicating strategic collaboration potential in R&D.
- Global Commercialization Rights: Gilead will retain sole worldwide commercialization rights (excluding Greater China), paying Galapagos royalties of 20%-23% of net sales, which will aid Gilead's further expansion in global markets.
See More
GILEAD TO PURCHASE ALL OUTSTANDING EQUITY OF OURO MEDICINES FOR $1.675 BILLION IN CASH UPFRONT
Acquisition Announcement: Gilead will acquire all outstanding equity of Oura for a total of $1.675 billion in upfront cash consideration.
Strategic Move: This acquisition is part of Gilead's strategy to enhance its portfolio in the healthcare sector.
See More
Gilead Sciences to Purchase Ouro Medicines to Enhance Innovative T Cell Engager Initiative for Autoimmune Disorders
Acquisition Announcement: Gilead Sciences has announced its acquisition of Ouro Medical to enhance its capabilities in treating autoimmune diseases.
Focus on Innovation: The acquisition aims to advance Gilead's first-in-class cell engager program, which is designed to target and treat autoimmune conditions more effectively.
See More
Gilead to Provide $1.5 Billion in Cash Upfront to Ouro's Private Investors, with Potential for an Additional $500 Million Based on Clinical Trial Success - FT
- Investment Details: Gilead will pay its privately held investors approximately $1.5 billion upfront in cash.
- Additional Funding: The deal includes at least an extra $500 million tied to specific clinical trial milestones.
See More
Gilead Approaches $2 Billion Agreement with Autoimmune Biotech Ouro Medicines - FT
Gilead's Major Deal: Gilead Sciences is nearing a $2 billion deal focused on autoimmune biotechnologies, indicating a significant investment in this area of medicine.
Focus on Biotech: The deal highlights Gilead's strategic shift towards developing innovative treatments in the biotechnology sector, particularly for autoimmune diseases.
See More
Gilead Acquires Ouro Medicines to Enhance Portfolio
- Acquisition Agreement: Gilead Sciences has entered into a definitive agreement to acquire Ouro Medicines for $1.675 billion in upfront cash, with an additional $500 million in potential milestone payments, aimed at strengthening its portfolio in inflammation and autoimmune diseases.
- Introduction of New Therapy: The acquisition includes OM336 (gamgertamig), a clinical-stage BCMAxCD3 T cell engager designed for rapid and deep B cell depletion, which is expected to enter registrational studies in 2027, demonstrating strong early efficacy and a differentiated safety profile after a single treatment cycle.
- Collaborative R&D Plans: Gilead is in advanced discussions with Galapagos NV for a potential research and development collaboration related to the acquired assets, where Galapagos would fund 50% of the upfront and milestone payments and manage most of Ouro's operations and employees.
- Global Commercialization Rights: Gilead will retain global commercialization rights excluding Greater China and will pay Galapagos royalties ranging from 20% to 23% of net sales, indicating a strategic positioning in the global market.
See More
Gilead Acquires Ouro Medicines for $1.675 Billion, Expanding Inflammation Portfolio
- Acquisition Scale: Gilead Sciences announced its acquisition of Ouro Medicines for a total of $1.675 billion, which includes $1.675 billion in upfront cash and up to $500 million in milestone payments, reflecting the company's strong investment intent in the biotech sector.
- Product Line Expansion: This acquisition adds OM336 (gamgertamig) to Gilead's inflammation portfolio, a clinical-stage BCMAxCD3 T cell engager designed for rapid and deep B cell depletion through a limited subcutaneous treatment, expected to enter registrational studies in 2027.
- Collaborative R&D Opportunities: Gilead is in advanced discussions with Galapagos regarding the acquired Ouro Medicines assets, with Galapagos set to cover 50% of the upfront consideration and any milestone payments, indicating strategic collaboration potential in R&D.
- Global Commercialization Rights: Gilead will retain sole worldwide commercialization rights (excluding Greater China), paying Galapagos royalties of 20%-23% of net sales, which will aid Gilead's further expansion in global markets.
See More
